DCGI Financial News

New Delhi: Drugmaker Abbott India has voluntarily recalled several batches of antacid Digene Gel after the Drug Controller General of India (DCGI) issued an advisory against using the product. The regulator said that the impugned product, manufactured at the company’s Goa unit, may be unsafe, and could result in adverse effects when consumed.

Drugs Controller General of India has issued an advisory for patients and healthcare professionals to discontinue the use of popular antacid Digene gel due to safety concerns after drugmaker Abbott initiated a voluntary recall of the impugned product. According to the advisory by the drug regulator, doctors and healthcare professionals should carefully prescribe and inform their patients to «discontinue» its use. It has also asked them to report any adverse drug reaction (ADRs) arising due to its consumption.

DCGI) on Thursday held fresh consultations with stakeholders on the draft rules to regulate e-pharmacies, amid the Delhi High Court asking the government to inform it about the outcome of deliberations on the draft rules with stakeholders. The court was hearing pleas seeking a ban on «illegal» sale of drugs online. It had granted six weeks to the Centre and the next date of hearing is August 28. The DCGI held a meeting on Thursday which was attended by representatives from the chemists' body, All India Organization of Chemists and Druggists (AIOCD), representatives from the Pharmacy Council of India and representatives from online pharmacy platforms including Tata 1 mg, Pharm easy, Netmed, Practo, among others. India's online pharmacies that currently operate in a regulatory grey area.

New Delhi: The Drugs Controller General of India (DCGI) Rajeev Raghuvanshi has issued advisory for doctors, medical professionals and patients using pholcodine containing cough syrups and cold remedies by recommending them stop using such cough syrups after World Health Organsiation (WHO) alerted about the safety concern in cough syrups. WHO has warned healthcare professionals and regulatory authorities of the risk of anaphylactic reactions in the people who have taken pholcodine containing cough syrups and cold remedies atleast 12 months prior to surgical procedures involving the administration of general anesthesia with neuromuscular blocking agents (NMBAS).

The Drug Controller General of India (DCGI) on February 6 granted emergency use authorisation to Sputnik Light in India, making it the first single-dose COVID-19 vaccine to be approved for use in the country.